Literature DB >> 28653264

Survival analysis of patients with systemic lupus erythematosus in a tertiary hospital in southern Brazil.

Jordana Vaz Hendler1, Lucian de Souza1, Daniele Corrêa de Freitas Zernow1, Juliano Guimarães1, Thiago Bertotto1, Carla Forgiarini Saldanha1, João Carlos Tavares Brenol2, Odirlei André Monticielo3.   

Abstract

Systemic lupus erythematosus (SLE) treatments progress over the years. However, the mortality remains higher than in the general population. Few studies have examined SLE patients' survival in Brazil. This study aims to identify the main characteristics and risk factors to predict mortality and recognize the main causes of death in Brazilian patients with SLE. We retrospectively assessed clinical, demographic, and serological characteristics from 600 patients followed since 2001 in SLE outpatient clinic from Hospital de Clínicas de Porto Alegre. Risk factors for mortality were examined by univariate and multivariate Cox proportional hazards regression analyses. A p < 0.05 was considered significant. There were 527 survivors (87.83%). The main causes of death were cardiovascular disease (17%), infection (17%), and infection and SLE activity (17%). Risk factors for death were age at diagnosis (HR 1.065, CI 95% 1.039-10.092), SLICC damage index (HR 1.299, CI 95% 1.076-1569), antiphospholip syndrome (HR 3.021, CI 95% 1.307-6.985), and metilprednisolone pulse (HR 2.628, CI 95% 1.283-5.383). Antimalarials was a protective factor for death (HR 0.191, CI 95% 0.064-0.570). Cardiovascular disease, infection, and SLE activity associated with infection were the main known causes of deaths in our SLE patients. Secondary antiphospolipid syndrome, highest score in SLICC damage index, advanced age at diagnosis, and high dose of corticosteroids were risk factors for mortality. Antimalarials was an important protective factor.

Entities:  

Keywords:  Mortality; Survival; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2017        PMID: 28653264     DOI: 10.1007/s10067-017-3735-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  27 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

4.  Mortality profile related to systemic lupus erythematosus: a multiple cause-of-death analysis.

Authors:  Deborah C C Souza; Augusto H Santo; Emilia I Sato
Journal:  J Rheumatol       Date:  2012-01-15       Impact factor: 4.666

5.  Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L).

Authors:  Graciela S Alarcón; Gerald McGwin; Ana M Bertoli; Barri J Fessler; Jaime Calvo-Alén; Holly M Bastian; Luis M Vilá; John D Reveille
Journal:  Ann Rheum Dis       Date:  2007-03-27       Impact factor: 19.103

Review 6.  Diagnosis and classification of the antiphospholipid syndrome.

Authors:  Jose A Gómez-Puerta; Ricard Cervera
Journal:  J Autoimmun       Date:  2014-01-24       Impact factor: 7.094

Review 7.  Impact of race and ethnicity in the course and outcome of systemic lupus erythematosus.

Authors:  Luis Alonso González; Sergio M A Toloza; Graciela S Alarcón
Journal:  Rheum Dis Clin North Am       Date:  2014-06-07       Impact factor: 2.670

8.  Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies.

Authors:  Marko Yurkovich; Kateryna Vostretsova; Wenjia Chen; J Antonio Aviña-Zubieta
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-04       Impact factor: 4.794

Review 9.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03

Review 10.  Long-term survival and death causes of systemic lupus erythematosus in China: a systemic review of observational studies.

Authors:  Ziqian Wang; Yanhong Wang; Rongrong Zhu; Xinping Tian; Dong Xu; Qian Wang; Chanyuan Wu; Shangzhu Zhang; Jiuliang Zhao; Yan Zhao; Mengtao Li; Xiaofeng Zeng
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

View more
  2 in total

1.  Intranasal Methylprednisolone Ameliorates Neuroinflammation Induced by Chronic Toluene Exposure.

Authors:  Manuel F Giraldo-Velásquez; Iván N Pérez-Osorio; Alejandro Espinosa-Cerón; Brandon M Bárcena; Arturo Calderón-Gallegos; Gladis Fragoso; Mónica Torres-Ramos; Nayeli Páez-Martínez; Edda Sciutto
Journal:  Pharmaceutics       Date:  2022-06-02       Impact factor: 6.525

Review 2.  The landscape of systemic lupus erythematosus in Brazil: An expert panel review and recommendations.

Authors:  Evandro Mendes Klumb; Morton Scheinberg; Viviane Angelina de Souza; Ricardo Machado Xavier; Valderilio Feijo Azevedo; Elizabeth McElwee; Mariana Rico Restrepo; Odirlei André Monticielo
Journal:  Lupus       Date:  2021-07-13       Impact factor: 2.911

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.